Chitosan / PVA / exosome nanofiber membrane as well as preparation method and application thereof

The chitosan/PVA/exosome nanofiber membrane prepared by electrospinning solves the hydrophilicity problem and improves the repair effect of spinal cord injury. By adjusting the fiber arrangement and loading exosomes of the fiber membrane, it significantly improves the Repair effect of spinal cord injury.

CN119075001APending Publication Date: 2024-12-06SHANDONG FIRST MEDICAL UNIV & SHANDONG ACADEMY OF MEDICAL SCI
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411209991.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-30
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The existing chitosan/PVA nanofiber membranes face hydrophilic problems in spinal cord injury repair. They are too large to dissolve in water and are not conducive to long-term existence. They are too small to be unfavorable to liquid adsorption, which limits the Its repair effect.

Method used

Chitosan/PVA/exosome nanofiber membranes were prepared by electrospinning, and the fiber alignment directionality and diameter uniformity of the fiber membranes were adjusted. Combined with moderate hydrophilicity, a 1:9 chitosan/PVA ratio was used to adjust the fibers. , and a fiber membrane was obtained after heat treatment, loading exosomes to enhance the repair effect.

Benefits of technology

It improves the cellular compatibility and mechanical properties of nanofiber membranes, enhances the repair effect of spinal cord injuries, reduces scar formation, promotes the regeneration of neurons and blood vessels, and significantly improves the recovery of spinal cord function.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119075001A_ABST
    Figure CN119075001A_ABST
Patent Text Reader

Abstract

The invention discloses a chitosan / PVA / exosome nanofiber membrane as well as a preparation method and application thereof, and belongs to the technical field of spinal cord injury repair materials. The preparation method of the chitosan / PVA / exosome nanofiber membrane comprises the following steps that 1, chitosan is dissolved in glacial acetic acid to prepare a solution A, the amount of the chitosan is 1-2 g, the amount of the glacial acetic acid is 47-49 g, and the stirring time is 3-5 h; (2) PVA powder is dissolved in double distilled water, a solution B is obtained, the amount of the PVA powder is 4-5 g, the amount of the double distilled water is 44-47 g, and the stirring time is 10-14 h; (3) mixing the solution A and the solution B in the steps (1) and (2) according to a ratio of 1: 9 to obtain a spinning solution A1; and (4) adding 1 * 10 < 9 > exosomes into the spinning solution A1 obtained in the step (3), carrying out ultrasonic treatment, and preparing the chitosan / PVA / exosome nanofiber membrane through an electrostatic spinning injector.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of spinal cord injury repair materials, and in particular relates to a chitosan / PVA / exosome nanofiber membrane and a preparation method and application thereof. Background Art

[0002] Spinal cord injury is a serious, complex, and disabling traumatic central nervous system disease, which mainly includes primary injury and secondary injury. The destruction of neurons and glial cells after injury (generally within 2 hours) is primary injury; the subsequent uncontrolled destructive cascade reaction, accompanied by abnormal molecular signaling, production of reactive oxygen species ROS, inflammatory response, neuronal cell death, glial scar formation, etc., is secondary injury. The severity of the injury is largely determined by the degree of secondary injury. Therefore, to reduce the high mortality rate associated with spinal cord injury, timely intervention and treatment of related reactions such as inflammation in secondary injury are necessary. Depending on the degree of spinal cord damage and the anatomical level of the spinal cord, patients may experience various neurological dysfunctions ranging from sensory impairment, motor impairment, autonomic dysfunction to paralysis and even death. Spinal cord injury patients not only cause pain and life burdens for individuals and families, but also bring huge economic burdens to society.

[0003] It has been found that immune protection can be produced through intercellular regulation. Exosomes can play the role of immune protection and directly promote the regeneration of nerve cells, and further promote the regeneration of axons, myelin and blood vessels. Exosomes can act on glial cells, monocytes / macrophages and dendritic cells in the treatment of spinal cord injury. After spinal cord injury, a large number of glial cells and inflammatory cells infiltrate locally, which worsens the condition. Studies have confirmed that polarized glial cells induced by exosomes can effectively inhibit the proliferation of spinal cord tissue scars, exosomes can promote the differentiation of local M1 macrophages into M2 macrophages, reduce inflammatory responses and promote the recovery of spinal cord function, and passive immunity mediated by mature and immature dendritic cells of spinal cord homogenate proteins are effective in the treatment of spinal cord injury. ERK1 / 2, STAT3 and CREB signaling pathways are classic signaling pathways for neuronal and axonal regeneration. Studies have found that exosomes derived from bone marrow mesenchymal cells can activate these signaling pathways and promote neuronal and axonal regeneration. Other studies have confirmed that exosomes can promote microvascular regeneration and functional recovery in mouse ischemia models and promote the reconstruction of spinal cord blood vessels.

[0004] In actual use, chitosan / PVA / exosome nanofiber membranes face hydrophilicity issues when repairing spinal cord injuries. From the perspective of spinal cord tissue, if the hydrophilicity of this nanofiber membrane is too high and it is easily soluble in water, it will not be conducive to the long-term existence of this nanofiber membrane in the body to play a repairing role; if the hydrophilicity is too low, it will not be conducive to the adsorption of liquids such as the extracellular matrix in the body by this nanofiber membrane. The characteristics of PVA that it will dissolve quickly or over-swell in a water environment limit its application, and the higher the chitosan content, the worse the hydrophilicity of this nanofiber membrane. Summary of the invention

[0005] One of the purposes of the present invention is to provide a method for preparing a chitosan / PVA / exosome nanofiber membrane, the preparation method comprising the following steps:

[0006] (1) dissolving chitosan in glacial acetic acid, and magnetically stirring at room temperature for a certain period of time to obtain solution A, wherein the amount of chitosan is 1-2 g, the amount of glacial acetic acid is 47-49 g, and the stirring time is 3-5 h;

[0007] (2) dissolving PVA powder in double distilled water, stirring at 90° C. for a certain period of time to obtain solution B, wherein the amount of PVA powder is 4-5 g, the amount of double distilled water is 44-47 g, and the stirring time is 10-14 h;

[0008] (3) mixing the solutions A and B described in steps (1) and (2) in a ratio of 1:9, and stirring at room temperature to obtain a spinning solution A1;

[0009] (4) Add exosomes to the spinning solution A1 described in step (3), with the amount of exosomes being 1×10 9 After ultrasound, the nanofibers were injected into the electrospinning syringe. Under a high-voltage power supply, the syringe extrusion rate and the distance between the spinning nozzle and the collector were controlled. The nanofibers were dried by hot air and finally the chitosan / PVA / exosome nanofiber membrane was obtained on the collector.

[0010] Preferably, in step (1), the amount of chitosan is 1.5 g, and the amount of glacial acetic acid is 48.5 g.

[0011] More preferably, the stirring time in step (1) is 4 hours.

[0012] More preferably, in step (2), the amount of PVA powder is 4.5 g, and the amount of double distilled water is 45.4 g.

[0013] More preferably, the stirring time in step (2) is 12 hours.

[0014] More preferably, the step (3) is stirred at room temperature for 12 h.

[0015] More preferably, the parameters of the electrospinning syringe in step (4) are set as follows: an applied positive voltage of 15 kV, a negative voltage of -2.5 kV, an injection pump speed of 0.4 mL / h, a distance between the syringe needle tip and the roller of 130 mm, a roller speed of 1000 r / min, and spinning is carried out at room temperature and a humidity of 20-25%.

[0016] The second object of the present invention is to provide a chitosan / PVA / exosome nanofiber membrane prepared by the above preparation method.

[0017] The third object of the present invention is to provide the use of the above-mentioned chitosan / PVA / exosome nanofiber membrane in the preparation of products for treating spinal cord injury.

[0018] Compared with the prior art, the present invention has the following beneficial effects:

[0019] (1) The present invention synthesizes chitosan / PVA / exosome nanofiber membrane by electrospinning, which has a simple process, is easy to operate, and has readily available raw materials and low cost.

[0020] (2) Chitosan / PVA nanofiber membrane has a high specific surface area, good mechanical properties, and good cell compatibility. Chitosan itself has certain antibacterial and anti-inflammatory effects, thus having some therapeutic effects on the treatment of spinal cord injury in rats. After loading exosomes, the chitosan / PVA / exosome nanofiber membrane has acquired the functions of exosome immune protection and direct promotion of nerve cell regeneration on the basis of chitosan / PVA nanofiber membrane, thus having a stronger therapeutic effect on spinal cord injury in rats.

[0021] (3) The chitosan / PVA / exosome nanofiber membrane with a ratio of 1:9 can improve the hydrophilicity problem faced when repairing spinal cord injuries. From the perspective of spinal cord tissue, if the hydrophilicity of this nanofiber membrane is too high and it is easily soluble in water, it will not be conducive to the long-term existence of this nanofiber membrane in the body to play a repairing role; if the hydrophilicity is too low, it will not be conducive to the adsorption of liquids such as the extracellular matrix in the body by this nanofiber membrane. The characteristics of PVA that it will quickly dissolve or over-swell in a water environment limit its application, and the higher the chitosan content, the worse the hydrophilicity of this nanofiber membrane. In order to maximize the repair of spinal cord tissue, this patent selected a 1:9 chitosan / PVA electrospun fiber membrane after heat treatment with the most consistent fiber arrangement direction, the most uniform fiber diameter and thickness, and relatively moderate hydrophilicity, with a diameter range of 12.767±23.394nm.

[0022] (4) In chitosan / PVA / exosome nanofiber membranes, the synergistic effect of chitosan / PVA and exosomes improves the effect of nanofiber membranes on the repair of spinal cord injury. In the experiment, in the experimental group using only chitosan / PVA nanofiber membranes, the scar condition at the spinal cord injury site of rats was reduced, the number of surviving neurons was larger, the area of ​​the spinal cord cyst cavity was reduced, and the motor function of the rat hind limbs was restored to a certain extent. The above phenomena indicate that chitosan / PVA nanofiber membranes can play a certain role in the treatment of spinal cord injury. Chitosan / PVA nanofiber materials have good mechanical properties and good cell compatibility, and chitosan itself has certain antibacterial and anti-inflammatory effects. These may be the reasons why chitosan / PVA nanofiber membranes can treat spinal cord injuries in rats to a certain extent. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 This is a characterization diagram of exosomes in Example 3.

[0024] Figure 2 This is the SEM image of the material prepared in Example 3. DETAILED DESCRIPTION

[0025] Example 1

[0026] This embodiment provides a method for preparing a chitosan / PVA nanofiber membrane, and the specific steps are as follows:

[0027] (1) Dissolve 1.5 g of chitosan in 48.5 g of glacial acetic acid and stir magnetically at room temperature for 4 h to obtain solution A;

[0028] (2) 4.5 g of PVA powder was dissolved in 45.5 g of double distilled water and magnetically stirred at 90° C. for 12 h to obtain solution B;

[0029] (3) The solutions A and B described in steps (1) and (2) are mixed in a ratio of 1:9, 2:8, 3:7, and 4:6, and the spinning solutions A1, A2, A3, and A4 are obtained after magnetic stirring at room temperature for 12 hours. After ultrasonic treatment for 10 minutes, the solutions are injected into the electrospinning syringe. Under a high voltage power supply, the syringe extrusion rate and the distance between the spinning nozzle and the collector are controlled. The chitosan / PVA nanofiber membrane is finally obtained on the collector by hot air drying. A positive voltage of 15 kV, a negative voltage of -2.5 kV, a syringe pump speed of 0.4 mL / h, a distance of 130 mm between the syringe needle tip and the roller, a roller speed of 1000 r / min, and spinning is performed at room temperature and a humidity of 20-25%. The prepared nanofiber membrane is placed in a precision air drying oven and dried at 50°C for 24 hours to remove the residual reaction solvent. The fiber membrane is then cut into 1 cm 2 The size was fixed on the workbench, the surface was sprayed with gold, and the morphology of each group of electrospun nanofiber membranes was observed using a scanning electron microscope.

[0030] It was observed that the directionality of the electrospun nanofibers in the chitosan / PVA ratio group of 1:9 was more consistent than that in other groups, and the thickness of the electrospun fibers was more uniform. Thirty electrospun fibers were randomly selected from each group, measured using Image J software, and the measured data were statistically analyzed. At room temperature, the diameters of the electrospun fibers in the ratios of 4:6, 3:7, 2:8, and 1:9 were 106.433±18.003nm, 110.633±36.546nm, 164.467±36.882nm, and 212.767±23.394nm, respectively. After heat treatment at 160℃ for 30min, the diameters of the electrospun fibers in each group were 96.100±18.581nm, 104 .633±20.891nm, 179.467±36.882nm, 212.767±23.394nm; The experimental results showed that there was no significant difference in the diameter of the electrospun fibers in each group before and after heat treatment at 160℃ (p>0.05). The diameter of the electrospun fibers in the 1:9 group was larger than that in the other three groups, followed by the diameter of the fibers in the 2:8 group (p<0.05), and there was no significant statistical difference in the diameter of the fibers in the 3:7 and 4:6 groups (p>0.05). As the proportion of chitosan decreased, the diameter of the electrospun nanofibers gradually increased.

[0031] Example 2

[0032] This embodiment provides a method for preparing a chitosan / PVA nanofiber membrane, and the specific steps are as follows:

[0033] (1) Dissolve 1.5 g of chitosan in 48.5 g of glacial acetic acid and stir magnetically at room temperature for 4 h to obtain solution A;

[0034] (2) 4.5 g of PVA powder was dissolved in 45.5 g of double distilled water and magnetically stirred at 90° C. for 12 h to obtain solution B;

[0035] (3) The solutions A and B described in steps (1) and (2) are mixed in a ratio of 1:9, 2:8, 3:7, and 4:6, and the spinning solutions A1, A2, A3, and A4 are obtained after magnetic stirring at room temperature for 12 hours, and injected into the electrospinning syringe after ultrasonic treatment for 10 minutes. Under a high voltage power supply, the syringe extrusion rate and the distance between the spinning nozzle and the collector are controlled, and the chitosan / PVA nanofiber membrane is finally obtained on the collector by hot air drying. The positive voltage is 15 kV, the negative voltage is -2.5 kV, the injection pump speed is 0.4 mL / h, the distance between the syringe needle tip and the roller is 130 mm, the rotation speed of the roller is 1000 r / min, and the spinning is carried out at room temperature and a humidity of 20-25%.

[0036] (4) The prepared electrospun nanofiber membranes in different proportions were placed in an oven and heated at 160°C for 1.5 hours for heat treatment.

[0037] (5) The electrospun fiber membrane was cut into 2cm×2cm size, and the water contact angle of the fiber membrane was measured using a contact angle tester to test the hydrophilicity of the fiber membrane. The water contact angles of the electrospun fiber membranes in different chitosan and PVA ratio groups were photographed. The water contact angles of the electrospun fiber membranes without heat treatment were all less than 40°, indicating good hydrophilicity. After heat treatment at 160°C, the water contact angles of the electrospun fiber membranes in each group increased to varying degrees. The water contact angles of the groups after heat treatment were calculated and compared. After heat treatment, the water contact angle of the 1:9 group was the smallest, and the water contact angle of the 4:6 group was the largest, with statistically significant differences (p<0.05). As the chitosan ratio decreased, the hydrophilicity of the electrospun nanofibers gradually increased.

[0038] Example 3

[0039] This embodiment provides a method for preparing a chitosan / PVA / exosome nanofiber membrane, and the specific steps are as follows:

[0040] (1) Dissolve 1.5 g of chitosan in 48.5 g of glacial acetic acid and stir magnetically at room temperature for 4 h to obtain solution A;

[0041] (2) 4.5 g of PVA powder was dissolved in 45.5 g of double distilled water and magnetically stirred at 90° C. for 12 h to obtain solution B;

[0042] (3) mixing the solutions A and B described in steps (1) and (2) in a ratio of 1:9, and magnetically stirring at room temperature for 12 hours to obtain a spinning solution A1;

[0043] (4) Cultivate bone marrow-derived mesenchymal stem cells and extract exosomes. 2-4 week old SD rats weighing 30-80 g were taken and killed by cervical dislocation. The rats were soaked in 75% alcohol for 10 min. The femurs and tibias on both sides were taken and repeatedly rinsed with PBS containing 1% double antibody. The epiphyses were cut open, and the bone marrow was flushed into a centrifuge tube with 20% FBS1% double antibody a-MEM until the bone heads turned white. The tissue blocks were blown with a pipette until there were no obvious lumps. The bone marrow suspension obtained from each side of the tibia and femur was inoculated in a culture dish, marked as P0, and the culture dish was placed at 37°C and 5% CO 2Culture in an incubator. When the primary cell fusion reaches 80-90%, cell passage is performed. Discard the supernatant, rinse twice with PBS, add 2mL of 0.25% trypsin to digest for about 1 minute, and add 4ml of complete culture medium to terminate the digestion when the cells shrink and become round and the intercellular connections are disconnected. The adherent cells are repeatedly blown off by the pipette, and the cell suspension is transferred to a 15mL centrifuge tube. Centrifuge at 1000rpm for 5min, and the resulting cell pellet is processed later. After resuspending the rat bone marrow mesenchymal stem cell pellet, it is inoculated in a new culture dish at a ratio of 1:2. Taking advantage of the characteristics of loose adhesion of bone marrow mesenchymal stem cells and tight adhesion of fibroblasts, bone marrow mesenchymal stem cells are gradually purified after multiple passages, and cells at passage P5 are used to extract exosomes. Exosomes are extracted from the cell supernatant by ultracentrifugation. Collect the supernatant of the subcultured P5 cells after 48 hours of culture, centrifuge at 300g for 10min, transfer the supernatant to a new tube, centrifuge at 2000g for 10min, transfer the supernatant to a high-speed centrifuge tube, centrifuge at 10000g for 30min, transfer the supernatant to an ultracentrifuge tube, centrifuge at 100000g for 75min, discard the supernatant, resuspend the precipitate with 50mL PBS, and ultracentrifuge again under the same conditions (the above centrifugation is all at 4°C), collect the exosomes from 6 ultracentrifuge tubes, resuspend the precipitate with 1mL PBS and divide it into 1.5mL centrifuge tubes, and place it in a 4°C refrigerator for use on the same day. The extracted exosomes were identified by scanning transmission electron microscopy, and the concentration of exosomes per milliliter was measured by flow cytometry. According to the relationship between concentration and volume, 1×10 9 Exosomes were used to prepare chitosan / PVA / exosome nanofiber membranes.

[0044] (5) Add 1×10 exosomes to 10 mL of spinning solution A1 described in step (3). 9 After magnetic stirring for 2 minutes at room temperature, spinning solution B was obtained. After ultrasonication for 10 minutes, it was injected into the electrospinning syringe. Under a high-voltage power supply, the syringe extrusion rate and the distance between the spinning nozzle and the collector were controlled. After hot air drying, chitosan / PVA / exosome nanofiber membrane was finally obtained on the collector. An external positive voltage of 15kV, a negative voltage of -2.5kV, an injection pump speed of 0.4mL / h, a distance of 130mm between the syringe needle tip and the roller, a roller speed of 1000r / min, and spinning was carried out at room temperature and a humidity of 20-25%. The prepared electrospun fiber membrane was placed in a precision air drying oven and dried at 50°C for 24 hours to remove residual reaction solvent. The fiber membrane was then cut into 1cm 2 The size was fixed on the workbench, the surface was sprayed with gold, and the morphology of each group of nanofiber membranes was observed using a scanning electron microscope.

[0045] In this embodiment, the volume ratio of chitosan to PVA is 1:9. After the exosomes are added, the exosomes are evenly distributed in the chitosan / PVA nanofiber material, and the nanofiber material loaded with exosomes has improved ability to repair spinal cord injury.

[0046] Application Example 1

[0047] SD rats were anesthetized by inhalation of isoflurane through an anesthesia machine, and the rats were placed prone on the operating table. The back hair was shaved 2 cm from the head and tail of the rats, with the size of 2 cm × 4 cm, with the T4 spinous process as the center. The skin was incised, the paravertebral muscles were separated, and the spinous processes and lamina of the T9-T11 segments were bitten off with bone rongeurs to expose the spinal cord at the T10 segment. A spinal cord percussion instrument was used, and a percussion head with a diameter of 2 mm was selected. The percussion parameters were set as follows: percussion speed 2.0 m / s, percussion depth 1.0 mm, and percussion head residence time 150 ms. The exposed spinal cord at the T10 level was percussed. After the percussion, the rat's tail and hind limbs trembled, indicating that the rat spinal cord injury model was successfully established.

[0048] After establishing the rat spinal cord injury model, the nanofiber membrane repair material was cut into 2mm×5mm size and placed on the impact site of the rat spinal cord to cover the injured area (about 2mm×4mm) and suture the skin layer by layer. Behavioral analysis, ELISA detection, HE staining, immunofluorescence staining and other methods were used to evaluate the effectiveness of the nanofiber membrane repair material in repairing rat spinal cord injury.

[0049] Basso Beattie Bresnahan (BBB) ​​score: At pre-set time points (before surgery, 1d, 3d, 7d, 14d, 21d, 28d after surgery), BBB score was performed, the animals were placed on an open platform, the walking and limb activities of the hind limbs were observed and the scores were recorded, and the average score of the left and right sides was taken. Two experimenters scored and recorded the results in a double-blind manner, and the average score was taken.

[0050] Footprint experiment: Each group of rats underwent a footprint experiment 28 days after surgery. The rats' forelimbs were dyed with blue ink and their hindlimbs were dyed with red ink. Then the rats were placed on white paper and walked in a straight line. The rat footprints were observed.

[0051] Observation of inflammatory changes in spinal cord injury: 7 days after surgery, blood was collected from the tail vein of each group of rats, and then the blood was centrifuged at 4°C at high speed (3000r / min, 10min), and serum was collected and stored at -80°C. After thawing the collected serum, the contents of tumor necrosis factor-α (TumorNecrosis Factor-α, TNF-α) and interleukin-10 (Interleukin-10, IL-10) in rat serum were detected according to the ELISA test instructions. The specific steps are as follows:

[0052] ① Add 50 μL of standard samples of different concentrations to each standard sample well;

[0053] ② Set up blank wells (without adding samples and enzyme-labeled reagents) and test sample wells. First add 40uL of sample diluent to the test sample well on the enzyme-labeled plate, then add 10μL of the test sample, and shake to mix;

[0054] ③Except for the blank well, add 100 μL of enzyme-labeled reagent to each well;

[0055] ④ Seal the plate with a sealing film and incubate at 37°C for 60 min;

[0056] ⑤ Dilute the concentrated washing solution 20 times with distilled water for later use;

[0057] ⑥ Remove the sealing film, discard the liquid, spin dry, fill each well with washing solution, let it stand for 30 seconds and then discard it, repeat 5 times, and pat the enzyme-labeled coated plate dry;

[0058] ⑦ First add 50 μL of color developer A to each well, then add 50 μL of color developer B, shake and mix, and color at 37℃ in the dark for 15 minutes;

[0059] ⑧Add 50 μL of stop solution to each well to terminate the reaction;

[0060] ⑨Measure the absorbance (OD value) of each well at a wavelength of 450nm

[0061] Obtaining spinal cord tissue: Rats were killed 28 days after SCI surgery and cardiac perfusion was performed. The specific steps were as follows: After the rats were anesthetized, the ribs were cut with scissors to expose the heart, and 200 mL of phosphate buffer salt (PBS) solution and 4% paraformaldehyde (PFA) solution were perfused in sequence. The spinal cord tissue at the T10 level was obtained. The spinal cord was fixed in 4% PFA for 24 hours, and then transferred to 20% sucrose PFA solution and 30% sucrose solution after 24 hours and 48 hours, respectively. All samples were stored at 4°C. The obtained spinal cord tissue was prepared into 20μm frozen pathological sections for subsequent experiments.

[0062] HE staining: In order to observe the pathological morphology of the spinal cord in each group, 20 μm frozen pathological tissues were stained with HE according to the manufacturer's instructions, and the images were observed under a microscope. The specific steps are as follows:

[0063] ① After the frozen sections returned to room temperature, they were fixed with 4% PFA for 5 minutes and washed with water for 5 minutes;

[0064] ② Hematoxylin staining for 2 minutes;

[0065] ③Differentiate with differentiation solution for 10 seconds, wash with water for 2 minutes;

[0066] ④ Debluing in bluing solution for 5 minutes, washing with water for 2 minutes;

[0067] ⑤Stain with eosin for 30 seconds and wash with tap water;

[0068] ⑥ Dehydration: 95% ethanol (Ⅰ) 2-3s, 95% ethanol (Ⅱ) 2-3s, 100% ethanol (Ⅰ) 2-3s, 100% ethanol (Ⅱ) 1min;

[0069] ⑦ Transparent: xylene (Ⅰ) 1 min, xylene (Ⅱ) 1 min;

[0070] ⑧Seal the slides: Seal the slides with neutral gum and observe under a microscope.

[0071] Immunofluorescence staining: In order to evaluate and compare the differences in astrocytes and neurons among the groups after spinal cord surgery, immunofluorescence staining of glial fibrillary acidic protein (GFAP) and neuronal nuclei (NeuN) was performed on frozen pathological tissues. The specific steps are as follows:

[0072] ① After the frozen sections return to room temperature, wash with PBS for 5 minutes, repeat 3 times;

[0073] ②Fix with 4% PFA for 30 min;

[0074] ③ Wash with PBS for 5 minutes, repeat 3 times;

[0075] ④1% PBST permeabilization for 15 min;

[0076] ⑤ Wash with 0.3% PBST for 5 min, repeat twice;

[0077] ⑥5% donkey serum blocking at room temperature for 1h;

[0078] ⑦ Wash with 0.3% PBST for 5 minutes, repeat twice;

[0079] ⑧Add primary antibody at 4℃ overnight; (mouse monoclonal Anti-GFAP antibody, 1:500) (mouse monoclonal Anti-NeuN antibody, 1:400)

[0080] ⑨Wash with 0.3% PBST for 5 min, repeat twice;

[0081] ⑩Add secondary antibody and incubate at 37℃ in dark for 1h; (Alexa 488 donkey anti-mouse, 1:800)

[0082] Wash with 0.3% PBST for 5 min, repeated twice;

[0083] Add DAPI mounting solution and mount the slides.

[0084] The embodiments described above are only descriptions of the preferred modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.

Claims

1. A method for preparing chitosan / PVA / exosome nanofiber membrane, It is characterized in that The preparation method comprises the following steps: (1) dissolving chitosan in glacial acetic acid, and magnetically stirring at room temperature for a certain period of time to obtain solution A, wherein the amount of chitosan is 1-2 g, the amount of glacial acetic acid is 47-49 g, and the stirring time is 3-5 h; (2) Dissolve PVA powder in deionized water and stir for a certain period of time to obtain solution B, wherein the amount of PVA powder is 4-5 g, the amount of deionized water is 44-47 g, and the stirring time is 10-14 h; (3) mixing the solutions A and B described in steps (1) and (2) in a ratio of 1:9, and stirring at room temperature to obtain a spinning solution A1; (4) Add exosomes to the spinning solution A1 described in step (3), with the amount of exosomes being 1×10 9 After ultrasound, the nanofibers were injected into the electrospinning syringe. Under a high-voltage power supply, the syringe extrusion rate and the distance between the spinning nozzle and the collector were controlled. The nanofibers were dried by hot air and finally the chitosan / PVA / exosome nanofiber membrane was obtained on the collector.

2. The preparation method according to claim 1, It is characterized in that In the step (1), the amount of chitosan is 1.5 g, and the amount of glacial acetic acid is 48.5 g.

3. The preparation method according to claim 2, It is characterized in that The stirring time in step (1) is 4 hours.

4. The preparation method according to claim 3, It is characterized in that In the step (2), the amount of PVA powder is 4.5 g, and the amount of double distilled water is 45.4 g.

5. The preparation method according to claim 4, It is characterized in that The stirring time of step (2) is 12 hours.

6. The preparation method according to claim 5, It is characterized in that In the step (3), the mixture was stirred at room temperature for 12 h.

7. The preparation method according to claim 6, It is characterized in that The parameters of the electrospinning syringe in step (4) are set as follows: an applied positive voltage of 15 kV, a negative voltage of -2.5 kV, an injection pump speed of 0.4 mL / h, a distance between the syringe needle tip and the roller of 130 mm, a roller speed of 1000 r / min, and spinning is performed at room temperature and a humidity of 20-25%.

8. Chitosan / PVA / exosome nanofiber membrane prepared by the preparation method according to any one of claims 1 to 7.

9. Use of the chitosan / PVA / exosome nanofiber membrane according to claim 8 in the preparation of a product for treating spinal cord injury.